Radiation Oncologist Makes Case for Radiotherapy for Local Treatment of Select Patients
Erin JungmeyerCan radiotherapy replace surgery in stage III NSCLC in the era of immunotherapy? During ELCC 23, Dr. Sara Ramella turned to the data to answer that question. Read more
Advocacy group says its annual research events are key to its mission: Making EGFR-mutated lung cancer a manageable chronic disease. Read more
Health Canada gives greenlight to cemiplimab-chemo combo for first-line treatment of advanced NSCLC. Early registration for WCLC 23 ends June 9. Read more
Air Pollution and Lung Cancer: A Q&A with Professor Charles Swanton
Erin JungmeyerDuring a recent interview with ILCN, Prof. Swanton reviewed the possible mechanisms at play when particulate matter triggers cancer growth and discussed new data that sheds additional light on the process. Read more
Advocate Terri Ann DiJulio knows the stigma associated with smoking must end if more lung cancer patients are to be diagnosed and treated early. The first step is talking about it. Read more
Amivantamab Demonstrates Consistent Efficacy in CHRYSALIS Follow-up
Erin JungmeyerSpain’s Dr. Pilar Garrido reviews long-term efficacy, safety, and predictors-of-response data for post-platinum advanced NSCLC patients with EGFR exon 20 insertion mutations. Read more
Early Detection Researcher Shares Epidemiologic Evidence on Air Pollution, Lung Cancer
Erin JungmeyerDr. Christine Berg says both smoking and air pollution are important in causing lung cancer. And both need to be eliminated to help prevent it and save lives. Read more
Analysis Shows Cancer Death Rates Must Decline Faster to Reach ‘Moonshot’ Goal
Erin JungmeyerA team of NCI researchers recently investigated what needs to happen for the United States to reach President Biden’s goal of cutting cancer mortality by 50% by 2047. Read more
Histologic Evaluation of Lung Cancer Invasion: More Difficult Than Meets the Eye
Mary Beth Beasley, MD+more
IASLC Pathology Committee members say the identification and evaluation of features that result in discordance in measuring invasive tumor size will hopefully improve reproducibility and lead to more accurate tumor staging moving forward. Read more
Primary AEGEAN Analysis Shows Improved EFS, pCR with Periadjuvant Durvalumab
Erin JungmeyerInvestigator Dr. John Heymach says the positive phase 3 data may lead to a potential new treatment option for patients with resectable NSCLC. Read more